Ironwood Pharmaceuticals, Inc.IRWD and its partner Allergan plc AGN announced that they have settled all pending patent litigations with Mylan Pharmaceuticals, Inc. MYL related to gastrointestinal ...

– The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – "With this license agreement, we have now preserved the majority of LINZESS patent ...

Ironwood Pharmaceuticals and Allergan reached a settlement with Teva over Teva’s abbreviated new drug application for a generic version of Linzess, a drug for irritable bowel syndrome with ...

Forest and Ironwood’s IBS drug Linzess (linaclotide), which won FDA approval last week for treatment of chronic constipation and irritable bowel syndrome with constipation, is expected by some ...

Ironwood Pharma remains undervalued despite a failed $1bn Vectiv Bio acquisition and subsequent stock plunge, with Linzess ...

Allegan, Forest Laboratories and Ironwood Pharmaceuticals accused Sandoz of patent infringement in a lawsuit to prevent Sandoz from bringing a generic version of Linzess to market, Delaware Law Weekly ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a supplemental new drug application for Linzess for the treatment of ...

Ironwood Pharmaceuticals and Allergan have reached an agreement with Sandoz resolving patent litigation brought in response to Sandoz’s ANDA seeking approval to market generic versions of Linzess ...

CAMBRIDGE, Mass. & DUBLIN--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Aurobindo ...

Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), has witnessed a strong uptake in recent quarters. The company markets Linzess in the United States in collaboration with ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for patent ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...